Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASEAN trade

This article was originally published in The Tan Sheet

Executive Summary

A trade agreement signed by the Association of Southeast Asian Nations Economic Ministers and a U.S. Trade Representative "will serve as a platform for further deepening and broadening [U.S. and ASEAN] trade and investment relations," according to an Aug. 25 media statement from the ASEAN Ministers. A Joint Council on Trade & Investment will be formed under the Trade & Investment Framework Arrangement (TIFA), and the nations will "establish a formal dialogue to address issues between them, to coordinate regional and multilateral trade issues and to undertake a Work Plan that will support regional integration and help build on the already strong trade and investment ties between them." Trade between ASEAN and the U.S. increased 12.4% between 2004 and 2005, reaching $152.9 bil., according to the release, which notes, "foreign direct investment also continued to rise." Separately, Ministers agreed to recommend ASEAN leaders accelerate the goal of establishing the ASEAN Economic Community, a single ASEAN market, from 2020 to 2015, the ministers announce Aug. 22...

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel